A detailed history of Principal Financial Group Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 12,160 shares of TSHA stock, worth $60,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,160
Previous 13,989 13.07%
Holding current value
$60,800
Previous $19,000 47.37%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 08, 2025

SELL
$1.13 - $2.9 $2,066 - $5,304
-1,829 Reduced 13.07%
12,160 $28,000
Q1 2025

Apr 28, 2025

SELL
$1.39 - $2.05 $1,364 - $2,013
-982 Reduced 6.56%
13,989 $19,000
Q4 2024

Jan 31, 2025

BUY
$1.27 - $3.24 $19,013 - $48,506
14,971 New
14,971 $25,000
Q3 2024

Oct 31, 2024

SELL
$2.01 - $2.46 $11,678 - $14,292
-5,810 Reduced 26.89%
15,799 $31,000
Q2 2024

Jul 29, 2024

BUY
$2.04 - $4.17 $44,082 - $90,109
21,609 New
21,609 $48,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $242M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.